Navigation Links
AMICAS Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2007
Date:2/28/2008

2007 2006

Operating activities

Loss from continuing operations $(862) $(1,254)

Gain from discontinued operations - 230

Net loss (862) (1,024)

Adjustments to reconcile net income (loss) to cash

used in operating activities:

Gain from the sale of discontinued operations - (230)

Depreciation and amortization 1,119 1,238

Provisions for bad debts, returns and discounts 185 746

Gain on sale of fixed assets - (6)

Amortization of software development costs 1,957 1,958

Non-cash stock compensation expense 1,878 1,763

Changes in operating assets and liabilities:

Accounts receivable 719 3,184

Prepaid expenses and other 1,100 (2,558)

Accounts payable and accrued expenses 1,768 (3,549)

Deferred revenue including unearned discount (889) 2,043

Cash provided by (used in) operating activities 6,975 3,565

Investing activities

Proceeds from sale of assets - 6

Purchases of property and equipment (510) (921)

Purchases of software (2,300) -

Purchases of held-to-maturity securities (94,898) (49,094)

Maturities of held-to-maturity securities 100,263 22,762

Purchases of available-for-sale securities (45,275) (48,405)

Sales of available-for-sale securities 37,340 10,297

Cash (used in) provided by investing activities (5,380) (65,355)

Financing activiti
'/>"/>

SOURCE AMICAS, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine news :

1. AMICAS Schedules Fourth Quarter and 2007 Year End Earnings Results Conference Call
2. AMICAS to Present at UBS Global Healthcare Services Conference
3. MedQuest Standardizes on AMICAS Vision Series PACS
4. AMICAS Solutions Closing the Loop in Radiology Communications
5. AMICAS Transforms Critical Results Notification with RadStream
6. AMICAS Launches Vision Reach 2.0, a Tool to Help Radiology Businesses Grow
7. Webcast Alert: AMICAS, Inc. Announces 3rd Quarter 2007 Earnings Conference Call
8. Radiology Ltd. Chooses AMICAS as End-to-End Solutions Provider
9. AMICAS Schedules Third Quarter Earnings Call
10. AMICAS to Present at William Blair & Company Small Cap Growth Stock Conference
11. AMICAS Hosts Complimentary DRA Education Session Featuring Timothy Trysla
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Mach 7 Technologies Contracted by Singapore General Hospital to Provide State-of-the-Art Patient Image Management Technology 2Mach 7 Technologies Contracted by Singapore General Hospital to Provide State-of-the-Art Patient Image Management Technology 3Ameritox(R) Appoints Jay B. Zimmerman as Chief Operating Officer 2Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 2Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 3Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 4Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 5Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 6Reportlinker Adds World Market for Cancer Therapeutics and Biotherapeutics 3rd Edition The Report 14262 1Reportlinker Adds World Market for Cancer Therapeutics and Biotherapeutics 3rd Edition The Report 14262 2Reportlinker Adds World Market for Cancer Therapeutics and Biotherapeutics 3rd Edition The Report 14262 3Reportlinker Adds World Market for Cancer Therapeutics and Biotherapeutics 3rd Edition The Report 14262 4Reportlinker Adds World Market for Cancer Therapeutics and Biotherapeutics 3rd Edition The Report 14262 5Reportlinker Adds World Market for Cancer Therapeutics and Biotherapeutics 3rd Edition The Report 14262 6Reportlinker Adds World Market for Cancer Therapeutics and Biotherapeutics 3rd Edition The Report 14262 7Reportlinker Adds World Market for Cancer Therapeutics and Biotherapeutics 3rd Edition The Report 14262 8Reportlinker Adds World Market for Cancer Therapeutics and Biotherapeutics 3rd Edition The Report 14262 9Reportlinker Adds World Market for Cancer Therapeutics and Biotherapeutics 3rd Edition The Report 14262 10Reportlinker Adds World Market for Cancer Therapeutics and Biotherapeutics 3rd Edition The Report 14262 11Reportlinker Adds World Market for Cancer Therapeutics and Biotherapeutics 3rd Edition The Report 14262 12Reportlinker Adds World Market for Cancer Therapeutics and Biotherapeutics 3rd Edition The Report 14262 13Reportlinker Adds World Market for Cancer Therapeutics and Biotherapeutics 3rd Edition The Report 14262 14Reportlinker Adds World Market for Cancer Therapeutics and Biotherapeutics 3rd Edition The Report 14262 15Reportlinker Adds World Market for Cancer Therapeutics and Biotherapeutics 3rd Edition The Report 14262 16Reportlinker Adds World Market for Cancer Therapeutics and Biotherapeutics 3rd Edition The Report 14262 17Reportlinker Adds World Market for Cancer Therapeutics and Biotherapeutics 3rd Edition The Report 14262 18The 60th Annual Meeting of the American Association for the Study of Liver Diseases Boston MA Hynes Convention Center October 31 November 3 20 5061 1The 60th Annual Meeting of the American Association for the Study of Liver Diseases Boston MA Hynes Convention Center October 31 November 3 20 5061 2American Society of Plastic Surgeons hosts 78th annual meeting 58275 1American Society of Plastic Surgeons hosts 78th annual meeting 58275 2American Society of Plastic Surgeons hosts 78th annual meeting 58275 3